---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009526"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T00:59:15.273457+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Coherus sells YUSIMRY (adalimumab-aqvh) to HKF for $40M upfront cash

## Summary
- Upfront all-cash consideration of $40M; closing occurred June 26, 2024.
- HKF's subsidiary Meitheal will commercialize YUSIMRY in the U.S.
- HKF assumes $17M in inventory purchase commitments; Coherus retains certain excluded assets/liabilities.
- Divestiture aligns with Coherus' strategic focus on oncology; proceeds to bolster cash position.
- Coherus retains oncology assets including LOQTORZI, UDENYCA franchise, and immuno-oncology pipeline.

## SEC filing metadata
- accession: 0001558370-24-009526
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837024009526/0001558370-24-009526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837024009526/chrs-20240626x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009526
- JSON: https://secwatch.observer/filing/0001558370-24-009526.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009526.txt

## Key facts
- M&A Transactions
  Coherus Oncology, Inc. completed a disposition involving Hong Kong King-Friend Industrial Company Ltd. for upfront, all-cash consideration of $40.0 million (closed 2024-06-26).
  - Action: disposition
  - Counterparty: Hong Kong King-Friend Industrial Company Ltd.
  - Consideration: upfront, all-cash consideration of $40.0 million
  - Closing: 2024-06-26
  source text: commitments, but not including certain identified excluded assets and excluded liabilities (collectively, the “YUSIMRY Disposition”) for upfront, all-cash consideration of $40.0 million paid on June 26, 2024. ​ The Purchase Agreement also provides for indemnification rights related to breaches of each party’s representations, warranties, covenants and certain
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837024009526/0001558370-24-009526-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.